Owens & Minor (NYSE:OMI) Reaches New 12-Month Low Following Analyst Downgrade

Shares of Owens & Minor, Inc. (NYSE:OMI – Get Rating) hit a new 52-week low during trading on Thursday after Citigroup lowered their price target on the stock from $20.00 to $17.00. Citigroup currently has a neutral rating on the stock. Owens & Minor traded as low as $14.09 and last traded at $14.09, with a volume of 738436 shares traded. The stock had previously closed at $14.62.

Several other research firms also recently issued reports on OMI. Robert W. Baird decreased their price objective on shares of Owens & Minor from $23.00 to $18.00 and set a “neutral” rating for the company in a research note on Wednesday, March 1st. Credit Suisse Group decreased their price objective on shares of Owens & Minor from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.20.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OMI. Advisor Group Holdings Inc. boosted its stake in Owens & Minor by 10.1% during the 1st quarter. Advisor Group Holdings Inc. now owns 4,858 shares of the company’s stock valued at $214,000 after acquiring an additional 444 shares during the last quarter. American Century Companies Inc. boosted its stake in Owens & Minor by 31.9% during the 1st quarter. American Century Companies Inc. now owns 29,981 shares of the company’s stock valued at $1,320,000 after acquiring an additional 7,258 shares during the last quarter. US Bancorp DE boosted its stake in Owens & Minor by 67.4% during the 1st quarter. US Bancorp DE now owns 1,145 shares of the company’s stock valued at $51,000 after acquiring an additional 461 shares during the last quarter. Natixis Advisors L.P. boosted its stake in Owens & Minor by 21.9% during the 1st quarter. Natixis Advisors L.P. now owns 14,557 shares of the company’s stock valued at $641,000 after acquiring an additional 2,612 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Owens & Minor by 20.0% during the first quarter. Bank of Montreal Can now owns 28,979 shares of the company’s stock worth $1,305,000 after purchasing an additional 4,823 shares during the period.

Owens & Minor Stock Down 4.4 %

The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of 49.93, a PEG ratio of 10.11 and a beta of 0.60. The stock’s fifty day simple moving average is $19.61 and its two-hundred day simple moving average is $21.17. The company has a debt-to-equity ratio of 2.63, a current ratio of 1.47 and a quick ratio of 0.61.

Owens & Minor (NYSE:OMI – Get Rating) last issued its earnings results on Tuesday, February 28th. The company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.11). The business had revenue of $2.55 billion for the quarter, compared to analyst estimates of $2.46 billion. Owens & Minor had a return on equity of 19.29% and a net margin of 0.22%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the company posted $0.81 earnings per share. On average, sell-side analysts predict that Owens & Minor, Inc. will post 1.18 earnings per share for the current fiscal year.

Owens & Minor Company Profile

(Get Rating)

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments. The Products and Healthcare Services segment includes medical distribution, the outsourced logistics and value-added services business, and global products, which manufacture and source medical surgical products through the production and kitting operations.